An Open, Pared Trial of Recombinant Hepatitis E Vaccine (Escherichia Coli) Hecolin® in the Chronic Hepatitis B Patients on the Clinical Stability ( Aged 30 Years or Over).

Trial Profile

An Open, Pared Trial of Recombinant Hepatitis E Vaccine (Escherichia Coli) Hecolin® in the Chronic Hepatitis B Patients on the Clinical Stability ( Aged 30 Years or Over).

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Dec 2017

At a glance

  • Drugs Recombinant hepatitis E vaccine (Hecolin) (Primary)
  • Indications Hepatitis E
  • Focus Therapeutic Use
  • Sponsors Xiamen Innovax Biotech
  • Most Recent Events

    • 01 Dec 2017 Status changed from active, no longer recruiting to completed.
    • 21 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top